Newsroom | 8226 results
Sorted by: Latest
-
Cardiac Amyloidosis Market Research 2025-2035 | Strategic Collaborations Accelerate Advances in Cardiac Amyloidosis Therapies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Cardiac Amyloidosis Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global cardiac amyloidosis market is experiencing substantial growth, driven by the increasing prevalence of amyloidosis-related cardiac conditions and the rising awareness among healthcare professionals and patients. Cardiac amyloidosis, characterized by the abnormal...
-
Leveragen and Propeller Bio Announce Strategic Collaboration to Advance Antibody and Protein Therapeutics
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen’s antibody discovery platforms through a strategic investment. In turn, Propeller wi...
-
The Vascular Care Group Welcomes Dr. Scott James as Newest Physician Partner
PLYMOUTH, Mass.--(BUSINESS WIRE)--The Vascular Care Group Welcomes Dr. Scott James as Newest Physician Partner...
-
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2025. Recent Highlights Q2 sales grew 11.9% to $1.53 billion, or 10.6% adjusted1, with strength across all product groups Q2 TAVR sales grew 8.9%; constant currency1 sales grew 7.8% Q2 TMTT sales reached $134.5 million or $133.0 million adjusted1, driven by PASCAL and EVOQUE Q2 EPS of $0.572; adjusted1 EPS of $0.67 SAPIEN platform is only TAVR approved for asymptomati...
-
FineHeart Named Leader of the IPCEI Health Tech4Cure to Spearhead the Structuring of the European Implantable Medical Device Sector
BORDEAUX, France--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, has been designated as the lead partner of the IPCEI Tech4Cure (Important Project of Common European Interest), dedicated to the implantable medical device (IMD) sector. This project is jointly notified by six EU Member States – France, Hungary, Italy, Latvia, Slovakia, and Slovenia FineHeart will carry out its SmartDMIA program to str...
-
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the second quarter of 2027, and positioning the company for sustained long-term growth. The restructuring and reprioritiz...
-
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approximately 8.6 million common shares at a purchase price of $3.50 per share. After deducting estimated offering expenses, t...
-
Vektor Medical’s vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
SAN DIEGO--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less...
-
GE HealthCare drives growth with investment in AI-enabled medical devices and tops FDA’s list of AI authorizations for 4th Year with 100
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device authorizations for the fourth year in a row with 100 listed authorizations to date in the U.S. This milestone reflects GE HealthCare’s continued research and development (R&D) investment and focus on developing AI solutions to advance precision care by enhancing medical devices across the care journey. Smart devices, software, and cloud-based solution...
-
Imperative Care Secures FDA Clearance and Initial Cases of the Zoom 7X Catheter, the Newest Innovation in Ischemic Stroke Treatment
CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care announces FDA 510(k) clearance and first patient cases with the novel Zoom 7X Catheter for aspiration thrombectomy procedures....